

**MINUTES OF THE MEETING OF THE NORTH CUMBRIA AREA PRESCRIBING COMMITTEE  
HELD ON THURSDAY 16<sup>th</sup> AUGUST 2018 AT 2.00PM  
MR2, ROSEHILL, CARLISLE**

Present: Bill Glendinning Chief Pharmacist, NCUHT (Chair)  
Andrea Loudon Clinical Pharmacy Lead, CCG  
Dr Andrea Mulgrew GP Prescribing Lead, Allerdale locality  
Helen Huck Chief Pharmacist, CPFT  
Helena Gregory Medicines Optimisation Pharmacist, NECS  
Phillip Utting Professional Secretary Cumbria APC & Senior  
Medicines Optimisation Technician, NECS

Also in attendance:

Jan Forlow Clinical Services Manager Pharmacy, NCUHT  
Andrew Ward Operations Manager Pharmacy, NCUHT  
Jo Thomas Specialist Pharmacist, Community Services, CPFT

---

**APOLOGIES FOR ABSENCE**

*Action*

Helen Seymour Senior Medicines Optimisation Pharmacist  
Dr Nirmalan Arulanantham Clinical Pharmacologist General Physician

---

**DECLARATION OF INTERESTS**

None received.

---

**MINUTES OF THE PREVIOUS MEETING**

The minutes of the previous meeting held on 14<sup>th</sup> June 2018 were approved.

---

**ACTION LOG FROM PREVIOUS MEETING (14<sup>th</sup> June 2018)**

Updates were given as follows:

13/18 – This action was completed  
14/18 – This action was completed  
19/18 – This action was completed  
20/18 – This action was completed  
21/18 – This action was completed  
22/18 – This action was completed  
23/18 – This action was completed  
25/18 – This action was completed

---

**15/17 Woundcare review**

HH to discuss with the TVN's and audit the prescribing of antibiotic and honey dressings across North Cumbria. Audit and results are due to be reviewed at the October 2018 APC meeting.  
ONGOING

HH

**53/17 NTAG – Paliperidone long acting injection (Xepilon®) and Paliperidone 3 monthly injection (Trevicta®) for schizophrenia** – Paliperidone 3 monthly injection (Trevicta®)

RECOMMENDED as per its licensed indications. – RED  
CPFT awaiting clear guidance until updating on how the SCG's system will operate when we move across to the North of Tyne APC and Formulary.  
ONGOING until decision is made.

**55/17 VSL#3 RAG rating review** – Noted no feedback from secondary care consultants. Also noted that this item is present in the ongoing NHSE consultation for conditions for which over the counter medicines should not be routinely prescribed in primary care, allowed for ACBS indication only. To be removed from current actions. COMPLETED

**60/17 Mesalazine MR prescribing** – NECS MO Pharmacist has contacted the secondary care gastroenterologists for advice around the switch and the referral of patients if necessary for review. NA to ask consultants for feedback on how they wish to proceed.  
ONGOING

NA

**72/17 Guidelines for the monitoring of IMD's** – Guidelines still in DRAFT format, to be presented at the next NoT Guideline group meeting for the NE & Cumbria. To be brought to the October 2018 APC meeting. ONGOING

HS

**04/18 Metolazone and Ranolazine prescribing** —The Metolazone Prescribing guideline is currently being updated to contain comments and further information around the monitoring aspects. To be brought to the October 2018 APC meeting. RAG rating to be changed to AMBER once approved.  
ONGOING

JF

**05/18 TA511 Brodalumab** - Treating moderate to severe plaque psoriasis -RED, Bluteq form to be added. PU to review the process. ONGOING

PU

**08/18 NG89: Venous thromboembolism in over 16's: reducing the risk of hospital-acquired DVT or PE** – Noted – Clive Graham NCUHT is now leading on this review within NCUHT. new protocol and local guideline to be written. JF to take over this action in BG absence. ONGOING

JF

**18/18 Colomycin nebulisers SCG** –BG to feedback to John Atkinson that a patient leaflet is required and also to confirm the patient review arrangements. The sundries needed on the SCG also to be reviewed to see what is exactly is required as these may not be available in primary care. JF to follow up.  
ONGOING

JF

**24/18 Transition to North of Tyne APC** – Formulary review details to be issued to all NCUHT, CPFT and NECS Pharmacists, this will be done over Sept 18. Details of formulary differences to be brought to the Oct 18 APC meeting for review. ONGOING

HG

---

60/18 **Recent North of Tyne Formulary decisions**

- **Noted that only the CCG commissioned items to be reviewed, all other NHSE commissioned items to be RED on RAG list.**

April 2018

**Insulin Degludec (Tresiba®)- Paediatric use** who cannot tolerate the sting associated with insulin glargine and in children and adolescents requiring supervised administration / flexibility around administration times. Noted – AMBER in line with North of Tyne, PU to inform paediatrics. ONGOING.

PU

**Dexmedetomidine (Dexdor®)-** For use in paediatric cardiac surgery for patients where surgery has a high risk of post-op Junctional Ectopic Tachyarrhythmia (JET) or for those suitable for fast track surgery. Noted – RED in line with North of Tyne

**HPV vaccine (Gardasil®)-** Therapeutic vaccination in the treatment of recurrent respiratory papillomatosis in children and adults. Noted – RED in line with North of Tyne

**Atomoxetine - ADHD therapy,** addition of 100mg capsules for those patients requiring high doses, 4mf/ml oral solution requested for patients with more complex needs eg younger patients with swallowing difficulties. Noted – remains AMBER with SCG in line with North of Tyne.

July 2018

**Tofacitinib citrate (Xeljanz®)-** In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately or who are intolerant to a DMARD. Noted – remains RED in line with North of Tyne

**Dexamethasone - Intravitreal implant** - Recommended as an option for treating non-infectious uveitis in the posterior segment of the eye in adults. – Noted – remains RED in line with North of Tyne

**Aviptadil with phentolamine mesilate (Invicorp®)** - For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic or mixed aetiology. Noted – AMBER in line with North of Tyne – HG to review North Cumbria CCG guidance. ONGOING.

HG

**Levonorgestrel (Kyleena®)** - Contraception for up to 5 years. Kyleena® produces a lower dose of progesterone than Mirena® and is similarly licensed for 5 years. Noted – Green in line with North of Tyne

**Fluticasone furoate, umecclidinium, vilanterol (as trifenate) (Trelegy® Ellipta®)** - Maintenance treatment in adult patients with moderate to severe COPD. Noted – Green in line with North of Tyne

**Lacosamide (Vimpat®)-** As **adjunctive therapy** in the treatment of partial onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. Noted – Remains AMBER in line with North of Tyne

**Lacosamide (Vimpat®)** - As **monotherapy therapy** in the treatment of partial onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. Noted – Remains AMBER in line with North of Tyne

---

- TA521** Guselkumab – Treating moderate to severe plaque psoriasis. – CCG commissioned -RED. – Bluteq form to be added. ONGOING. PU
- TA522** Pembrolizumab – Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable. – NHSE commissioned -RED.
- TA523** Midostaurin - Untreated acute myeloid leukaemia. - NHSE commissioned -RED.
- TA524** Brentuximab vendotin – Treating CD30 -positive Hodgkin lymphoma. - NHSE commissioned –RED.
- TA525** Atezolizumab - Treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. - NHSE commissioned –RED.
- TA526** Arsenic trioxide - Treating acute promyelocytic leukaemia - NHSE commissioned – RED.
- TA527** Beta interferons and glatiramer acetate - Treating multiple sclerosis - NHSE commissioned –RED.
- TA528** Niraparib - Maintenance treatment of relapsed platinum sensitive ovarian , fallopian tube and peritoneal cancer. - NHSE commissioned –RED.
- TA529** Crizotinib - Treating ROS1- positive advanced non-small-cell lung cancer - NHSE commissioned –RED.
- TA530** Nivolumab - Nivolumab is **not recommended**, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy.
- TA531** Pembrolizumab - For untreated PD-L1-positive metastatic non-small-cell lung cancer - NHSE commissioned –RED.
- TA532** Cenegermin - Cenegermin is **not recommended**, within its marketing authorisation, for treating moderate or severe neurotrophic keratitis in adults.
- TA533** Ocrelizumab - Treating relapsing – remitting multiple sclerosis - NHSE commissioned –RED.
- TA534** Dupilumab - Treating moderate to severe atopic dermatitis - CCG commissioned - RED. – Bluteq form to be added. Noted 30 day implementation for CCG’s. ONGOING. PU
- TA535** Lenvatinib and sorafenib - Treating differentiated thyroid cancer after radioactive iodine - NHSE commissioned –RED.
- TA536** Alectinib - For untreated ALK-positive advanced non-small-cell lung cancer - NHSE commissioned –RED.
- TA537** Ixekizumab - Treating active psoriatic arthritis after inadequate response to DMARDS - CCG commissioned -RED. – Bluteq form to be added. ONGOING. PU

---

**62/18 NICE CLINICAL GUIDELINES**

**NG97:** Dementia: assessment, management and support for people living with dementia and their carers. - Current SCG review to be done by CPFT and ICC leads to bring into line with this new guidance. Noted to be added to Prescription Pad. ONGOING. PU

**NG98:** Hearing loss in adults: assessment and management. - Noted to be added to Prescription Pad regarding electronic device. ONGOING. PU

**NG99:** Brain tumours (primary) and brain metastases in adults. Noted – No specific prescribing implications.

**NG100:** Rheumatoid arthritis in adults: management – Noted to be added to prescription pad the lack of evidence to support methotrexate injections. ONGOING. PU

**NG101:** Early and locally advanced breast cancer: diagnosis and management – Noted.

---

**63/18 NICE Medicines Optimisation NG5**

Nothing to discuss.

---

**64/18 CONTRACT MONITORING**

**RMOC briefing paper on Adalimumab** – noted for information. COMPLETED.

---

**65/18 MEDICINES SAFETY**

Sodium Valproate PREVENT programme currently being rolled out across North Cumbria. Practice patient data to be collated by the 31<sup>st</sup> August 2018, this to be sent to CPFT for review, HH to identify who in CPFT is the clinical lead to receive this data. HH

---

**CLINICAL MATTERS**

**66/18 Palliative Care Formulary RAG rating review** – Jo Thomas, Specialist Pharmacist Community Services, CPFT presented the committee with a list of common drugs used currently in Palliative care across North Cumbria. She showed the current North Cumbria RAG rating, the proposed current North of Tyne RAG formulary RAG rating and any differences / queries relating to each drug for its prescribing. The committee reviewed each drug separately and the decision on the most appropriate RAG rating was made. The results are shown in the table below. PU to update current RAG list.

Drug	Current North Cumbria RAG rating	North of Tyne RAG rating	Approved North Cumbria RAG rating
Midazolam Buccal Liquid	Buccolam – AMBER	Buccolam and Epistatus – both Green +	To be added for use in palliative care
Fentanyl (buccal)	Black	Black	Black
Fentanyl (intranasal)	Black	Black	Black
Fentanyl IR (sublingual)	AMBER	Green +	AMBER, the use of Actiq lozenges

			could be an option.
Buprenorphine	Black	Green +	AMBER for palliative care
Lidocaine patches	Green for licensed indications only	Green +	RED for non licensed indications
Alfentanil injection	Not listed	Green + for palliative care	AMBER for palliative care
Methadone injection	Not listed	Green +	AMBER for palliative care
Levomepromazine 6mg tablets	Not listed	Green (unlicensed)	GREEN – noted 25mg tablets to be split as 6mg are a special.
Methylnaltrexone	Black	Black	BLACK
Tapentadol IR	Black	Green +	AMBER for palliative care
Tapentadol SR	Green	Green +	AMBER
Dexamfetamine as an antidepressant	Amber	Amber	AMBER
Methylphenidate as an antidepressant	Amber	Amber	AMBER
Octreotide	Amber	Amber	AMBER for use in palliative care
Glycopyrronium	Amber	RED, this to be queried as part of core drugs	AMBER
Ketamine	Red	Amber	AMBER for use in palliative care- review shared care guideline
Lanreotide	Amber	Red	RED for use in palliative care
Ondansetron	Red	Green	Green for palliative care, oral tablets only

ONGOING

67/18 **Midazolam 10mg/2ml availability at NCUHT** – Jo Thomas, Specialist Pharmacist Community Services, CPFT presented the committee with the paper outlining the request to have Midazolam 10mg/2ml injection as stock in certain clinical areas with NCUHT to treat palliative care patients. BG informed the committee that the patient safety panel within NCUHT decided that all Midazolam 10mg/2ml injection be supplied on a named basis only against a prescription chart, no stock to be held on any ward. This was due to a patient safety incident in the past. BG and JF to feedback to the areas / wards where palliative care patients are to be treated to prescribe this drug for these patients earlier in their treatment pathway in the anticipation of its use. ONGOING.

JF

68/18 **Insulin passport** – The committee reviewed the insulin passport process and actual card and information sheets for patients, agreed that this would give patient choice across Cumbria, however it was noted that it would be the patient's responsibility to carry this card / information with up to date dose regimes. Further feedback to be brought to the October 2018 APC meeting from Cumbria Diabetes on how the passports will be issued to

HH  
HG

---

patients and from Community Pharmacies on their views of the scheme. HH to ask the diabetic champions within CPFT for their thoughts. ONGOING.

69/18 **RMOC – FOC Medicines Scheme** – Noted for information. COMPLETED.

70/18 **Buccal Midazolam & Rectal Diazepam guideline** – Guideline reviewed by the committee, APPROVED for use across North Cumbria. Noted that GP’s will receive a copy of the patient’s plan from CPFT. To be added to both Prescription Pad and CPFT Intranet. ONGOING. HH  
PU

71/18 **FreeStyle Libre supply** – AL informed the committee that she has received an email from a Cumbria Diabetes consultant stating that all supplies of FreeStyle Libre to patients across North Cumbria have currently stopped, this being due to a shortage of personnel to issue the prescriptions. Both HH and BG have been asked to take this back to their respective trusts to look at the issues involved and move the process forward as this was the agreed pathway for FreeStyle Libre supply. ONGOING. HH  
BG

72/18 **North of Tyne – Blood Glucose Monitoring guideline – Approved July 18** – Noted for information. COMPLETED.

73/18 **North of Tyne – Thyroid guidelines (TRAMP2) – Approved June 18** – Noted for information. COMPLETED.

74/18 **North of Tyne – Bariatric prescribing and monitoring for GPs – Approved June 18** – Noted for information. COMPLETED.

75/18 **North of Tyne – Lithium Shared Care – Approved June 18** – Noted for information. COMPLETED.

76/18 **North of Tyne – Cinacalcet in primary Hyperthyroidism – Approved June 18** – Noted for information. COMPLETED.

77/18 **North of Tyne – Melatonin Children and Young people – Approved June 18** – Noted for information. COMPLETED.

78/18 **North of Tyne – Methylphenidate for giggle incontinence- children – Approved July 18** – Noted for information. COMPLETED.

79/18 **North of Tyne – ADHD Adults Shared Care – Approved June 18** – Noted for information. COMPLETED.

80/18 **North of Tyne – ADHD Children Shared Care – Approved June 18** – Noted for information. COMPLETED.

81/18 **North of Tyne – Tocilizumab monitoring Shared Care – Approved June 18** – Noted for information. COMPLETED

---

## OPERATIONAL

82/18 **North East & Cumbria Prescribing Forum** – Awaiting further regional information on self-care and over-the-counter medicines.

83/18 **Transition to North of Tyne APC** – BG attended the last meeting – July 18  
Next meeting of the North of Tyne APC – 9<sup>th</sup> October 2018.

---

---

84/18

AL presented Bill Glendinning with a card and gift from the APC members to mark his retirement from NCUHT on the 31<sup>st</sup> August 2018 and to thank him for all his work with the APC.

---

**DRUG SAFETY UPDATE**

85/18 Drug Safety Update (June 2018) – Noted for information.

86/18 Drug Safety Update (July 2018) – Point 2 to be added to Prescription pad.

PU

---

87/18 **FOR INFORMATION**

**Minutes received:**

North of Tyne APC meeting – July 2018

---

**ANY OTHER BUSINESS**

88/18 **Asthma pathway - children** — Noted for information by the committee the current work around the Children's Asthma pathway, this information will be supplied to all families that have children with asthma.  
COMPLETED.

89/18 **ADHD in Adults Shared Care Guideline – North Cumbria** – The newly commissioned service across North Cumbria will use this SCG to cover all adult patients. To be added to NECS MO website and Prescription Pad. APPROVED. ONGOING

PU

---

**DATE and TIME of next meeting**

**Thursday 11<sup>th</sup> October 2018, 2pm at Conference Room, North Cumbria CCG Offices, Rosehill, Carlisle, CA1 2SE**

---